Showing 8101-8110 of 10613 results for "".
- Ulthera Cleared in Mexicohttps://practicaldermatology.com/news/20120320-ulthera_cleared_in_mexico/2459837/Ulthera is now registered in Mexico to market and distribute its ultrasound therapy device, the Ulthera System. In Mexico, the system is now prescribed to produce stimulation in tissues to raise the temperature in a localized manner for aesthetic
- Judge Blocks Launch of Xeomin for Aesthetic Indicationshttps://practicaldermatology.com/news/20120307-judge_blocks_launch_of_xeomin_for_aesthetic_indications/2459852/The planned March 12 launch of Merz's Xeomin (incobotulinumtoxinA) for aesthetic indications will almost certainly be delayed due to a court order blocking marketing of incobotulinumtoxinA. The order comes in response to a suit by
- FDA Approves Methoxsalen USP Providerhttps://practicaldermatology.com/news/20120229-fda_approves_methoxsalen_usp_provider/2459859/FDA has approved a secondary supplier of Methoxsalen USP, prescribed under the brand name Oxsoralen-Ultra® (methoxsalen) Capsules, USP, 10mg. Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, and marketer of the
- Analysis: Pediatric Allergic Rhinitis Doubled in Japan Over 40 Yearshttps://practicaldermatology.com/news/analysis-pediatric-allergic-rhinitis-doubled-in-japan-over-40-years/2487238/A 40-year epidemiologic analysis published in the World Allergy Organization Journal showed an increases in allergic rhinitis (AR), allergic conjunctivitis (AC), and Japanese cedar pollinosis (JCP) among school-aged children in western Japan, while rates of atopic dermatitis (AD) and bro
- PanOxyl Portfolio Highlights Accessibility and Long-Term Acne Management During Virtual Desksidehttps://practicaldermatology.com/news/panoxyl-portfolio-highlights-accessibility-and-long-term-acne-management-during-virtual-deskside/2487257/Acne management requires a broader approach than simply targeting active breakouts, according to speakers during a virtual media deskside hosted by Revance. The discussion focused on over-the-counter acne management strategies with the PanOxyl brand as well as procedural options for acne scar tre
- Randomized Trial Evaluates Educational Delivery Methods for Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/randomized-trial-evaluates-educational-delivery-methods-for-pediatric-atopic-dermatitis/2487170/A randomized controlled trial published online in Pediatric Dermatology found that video-based therapeutic patient education (TPE) did not significantly outperform standard educational handouts for pediatric atopic dermatiti
- Isotretinoin Use in Adolescence Not Linked to Reduced Adult Height: Analysishttps://practicaldermatology.com/news/isotretinoin-use-in-adolescence-not-linked-to-reduced-adult-height-analysis/2487168/Concerns that isotretinoin therapy during adolescence could impair skeletal growth were not supported by findings from a large nationwide Danish study published in
- BE BOLD: Bimekizumab Tops Risankizumab for ACR50 Outcomeshttps://practicaldermatology.com/news/be-bold-bimekizumab-tops-risankizumab-for-acr50-outcomes/2487139/New phase 3 data from the BE BOLD trial indicated that bimekizumab (BIMZELX) achieved superior joint efficacy compared with risankizumab (SKYRIZI) in adults with active psoriatic arthritis (PsA), according to a press release from the manufacturer.
- Combination Ixekizumab and Tirzepatide Therapy Outperforms Ixekizumab Alone in Psoriasishttps://practicaldermatology.com/news/combination-ixekizumab-and-tirzepatide-therapy-outperforms-ixekizumab-alone-in-psoriasis/2487115/Concomitant treatment with ixekizumab (Taltz, Eli Lilly and Company) and tirzepatide (Zepbound, Eli Lilly and Company) led to superior skin clearance and quality-of-life outcomes compared with ixekizumab alone in adults with moderate-to-severe plaque psoriasis and
- Text-Messaging Program Improves Cardiovascular Risk Behaviors in Psoriasishttps://practicaldermatology.com/news/text-messaging-program-improves-cardiovascular-risk-behaviors-in-psoriasis/2487068/Structured text-messaging interventions were associated with an improvement cardiovascular risk-related behaviors and patient activation in adults with psoriasis, according to new study results published online in JAMA Dermatology.